Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
Date:10/26/2009

NEW YORK, Oct. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that an abstract related to the clinical data of the 55-patient Phase 2 high-dose study of Zerenex (ferric citrate) has been accepted for presentation during the poster sessions to be held at the upcoming American Society of Nephrology (ASN) Renal Week Meeting and exposition taking place October 27-November 1 in San Diego, California.

Poster Number: PO-361, entitled "Evaluation of Ferric Citrate as a Phosphate Binder in Dialysis Patients Requiring High Doses of Phosphate Binders" will be presented on Thursday, October 29, 2009 at 10:00am PDT during the "Dialysis: Epidemiology, Outcomes, and Clinical Trials: Non-Cardiovascular I" Poster Session, and will be available for viewing from 10:00am-12:00pm PDT.

Top-line data from the study discussed in the poster was previously announced by the Company.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
2. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
3. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
4. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
5. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
7. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
8. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
9. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
10. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
11. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Pepperl+Fuchs, a world leader in process ... leading provider of HART protocol devices. The move ... its integrated solutions offerings and strengthen its position ... are pleased to add the MACTek WirelessHART product ... Bolin , Pepperl+Fuchs, executive vice president of the ...
(Date:8/31/2015)... Aug. 31, 2015  Ascendant Solutions, Inc. (Pink Sheets: ... that its Healthcare subsidiary, Dougherty,s Holdings, has acquired Springtown ... downtown square of Springtown, Texas , ... years, this community-based pharmacy has provided retail prescriptions, healthcare ... Springtown . The ...
(Date:8/31/2015)... 2015  Daktari Diagnostics today announced a collaboration with Merck, ... and Canada , to develop Daktari,s ... up to $8.5 million over the next 3.5 years, will ... regulatory approval of Daktari,s HCV test. The ... can detect low levels of virus directly in a single ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 2Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 3Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 2Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 3
(Date:9/1/2015)... ... September 01, 2015 , ... With former IBMers among its ... disciplines since its inception more than 35 years ago. A pilot program begun by ... teachers - and, not just those intent on pursuing careers in these fields. The ...
(Date:9/1/2015)... ... September 01, 2015 , ... WorkCare, Inc., a national ... medical management team as an Associate Medical Director. , WorkCare specializes in ... the U.S. and abroad. , Dr. Nelson has a diverse background. He ...
(Date:9/1/2015)... ... 01, 2015 , ... METTLER TOLEDO has announced an upcoming ... requirements“ , featuring Ed Szczesny (Quality Assurance, Rhodes Pharmaceuticals) as guest presenter. This ... , Calibration, qualification, and the appropriate level of routine testing for laboratory ...
(Date:9/1/2015)... ... 01, 2015 , ... Ogawa’s new massage chairs tout innovative functionality that change ... than ever before. With the goal of bringing wellness to the world, Ogawa introduces ... , As in its name, the Ogawa Refresh aims to “refresh” ...
(Date:9/1/2015)... ... September 01, 2015 , ... AdvantagePlusCaregivers.com® provides ... access caregivers and what to look for and expect when searching for resources, ... in 2006 in Canoga Park, CA by CEO, Richard Weatherman and Co-Founder Piroska ...
Breaking Medicine News(10 mins):Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2Health News:Ogawa World USA Releases New Massage Chairs to the US 2Health News:Ogawa World USA Releases New Massage Chairs to the US 3Health News:AdvantagePlusCaregivers.com® Launches New Website for Corporate and Franchisee Locations in 3 States 2
... polyps and their removal ... progress into cancer, OAK BROOK, Ill., Oct. 2 ... colonoscopy remains,the most effective screening option for colorectal cancer. ... cancer screening because it,allows the trained physician to thoroughly ...
... within the heath care,anti-fraud field., EASTON, Md., ... announced today that Cynthia Steedman, RN, BSN, Medical,Claims ... Health Care,Anti-Fraud Association (NHCAA) as an Accredited Health ... accomplishment,within the health care anti-fraud field., As ...
... common childhood condition , , TUESDAY, Oct. 2 (HealthDay ... on Tuesday released a guide intended to help ... and frightening information on treatments for attention-deficit hyperactivity ... on medications, the ADHD Parents Medication Guide ...
... FORT WORTH, Texas, Oct. 2 DSS Research announced ... SeniorTrax(R),survey. The survey was completed in late June and ... Only coverage are definitely or very likely,to switch to ... was conducted,nationally with 600 Medicare beneficiaries. Among those "not ...
... Corrected Announcement Follows, NEW YORK, Oct. 2 ... I. Craig Henderson, MD, the,Company,s President, will present an ... Blair & Company Small-Cap Growth Stock,Conference in New York ... 3rd at 12:00 noon ET. Dr. Henderson,s presentation ...
... WASHINGTON, Oct. 2 As Fred Thompson,campaigns in ... why he is standing,stubbornly behind President Bush,s threat ... income children, including 32,000 of Iowa,s kids.,[ http://www.governor.iowa.gov/news/2007/09/28_1.php ... Health Insurance Program,(SCHIP), saying, "It,s gotten totally out ...
Cached Medicine News:Health News:Colonoscopy Remains the Most Effective Screening Option for Colon Cancer 2Health News:Colonoscopy Remains the Most Effective Screening Option for Colon Cancer 3Health News:Colonoscopy Remains the Most Effective Screening Option for Colon Cancer 4Health News:Cynthia Steedman Earns Health Care Fraud Investigator Accreditation 2Health News:Doctors' Groups Offer ADHD Guide for Parents 2Health News:Doctors' Groups Offer ADHD Guide for Parents 3Health News:Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference 2Health News:DNC: Fred Thompson Stands With President Bush, Not Iowa's Kids 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: